Quest Diagnostics Inc. (DGX) News
Filter DGX News Items
DGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DGX News Highlights
- For DGX, its 30 day story count is now at 16.
- Over the past 16 days, the trend for DGX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about DGX are MA, DRUG and DVA.
Latest DGX News From Around the Web
Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare ConferenceQuest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time. |
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical OfficerQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately. |
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test PanelQuest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic. |
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid ArthritisRelationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE / December 19, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of ... |
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test PanelQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illi |
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index for Seventh Consecutive YearSECAUCUS, NJ / ACCESSWIRE / December 18, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has received a score of 100% on the Human Rights Campaign ... |
Investors Appear Satisfied With Quest Diagnostics Incorporated's (NYSE:DGX) ProspectsQuest Diagnostics Incorporated's ( NYSE:DGX ) price-to-earnings (or "P/E") ratio of 20x might make it look like a sell... |
Quest Diagnostics' (DGX) Haystack Oncology Inks New DealQuest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey. |
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast CancerHaystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized MRD technology (Haystack MRD™) to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer (TNBC) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin. Rut |
Quest Diagnostics Multi-Pronged Approach to Waste ReductionNORTHAMPTON, MA / ACCESSWIRE / December 13, 2023 / Quest Diagnostics Originally published in Quest Diagnostics Corporate Responsibility Report 20222025/2026 GoalsImplement a waste-to-energy strategy to divert from landfills' waste from several of ... |